


UNIQUE BOOK PROVIDES STRONG RATIONALE FOR GENETIC TESTING IN PSYCHIATRY

Book gives strong clinical evidence for more wide-spread use of pharmacogenetic testing in psychiatry

NEW YORK, NEW YORK, USA, September 21, 2017 /EINPresswire.com/ -- Genetic testing has revolutionized the way we treat cancer and many other serious diseases. But despite its availability and proven usefulness in psychiatry, it has not been widely adopted and used - despite its endorsement and frequent use in the psychiatry and neurology clinics at major medical centers. The authors of this new book felt there was a need to present a concise picture of the true effectiveness of pharmacogenetic technology. [Dr. David Durham](#) and Dr. Ranjit Thirumaran are renowned experts in the field of pharmacogenetic technology. Herb Goodman, M.D., Ph.D., president of the [American College of Neurocognitive Medicine](#) and a medical scientist who has been a principal investigator of more than one-hundred clinical drug trials, believes psychiatry is long-overdue in its adoption of pharmacogenetics. "The extraordinary cost of managing prescription drug side effects, and the high effective failure rate of psychotropic treatment is happening, in large part, because of the collective stubbornness of physicians to adopt clinical tools like genetic testing that is now proven to dramatically reduce side effect risk and improve response to treatment." He believes Drs. Durham and Thirumaran will be joined by more and more physicians, scientists and pharmacists calling for this technology to become the standard of care.



[Psychiatric Pharmacogenetics: from concepts to cases](#) provides a very compelling argument for its regular use in community level clinics throughout the United States. It is unique in that it is the only book in its category to provide more than a dozen detailed clinical cases where the use of pharmacogenetic technology substantially changed the course of treatment for patients and clearly improved outcomes. The book was first released by Fortis Caliga Press in January 2017. It has received high acclaim and has been included in the reading curricula of numerous university post graduate programs and medical schools.

Madison Park
The American Board of Neuropsychiatry
(800) 983-0747
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2017 IPD Group, Inc. All Right Reserved.